Dechert Advises Antios Therapeutics on $96 Million Series B Financing
April 14, 2021
Dechert advised Antios Therapeutics, Inc. (“Antios”) on the successful completion of a $96 million Series B financing.
Antios is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases.
The proceeds from this financing will support the ongoing Phase 2 clinical program which is evaluating the potential for Antios’s lead clinical candidate, ATI-2173, to be a backbone of a once-daily curative regimen for chronic hepatitis B.
The Dechert team includes corporate partner David Rosenthal and associates Tiffany Pan and Curtis Weber.
About Dechert LLP
Dechert is a leading global law firm with 25 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for clients.
